ProPhase - רווח נקי למניה בארבעת הרבעונים האחרונים PRPH

Declining post-pandemic diagnostic demand and genomics expenditures create profit risks for ProPhase Labs, Inc. (PRPH). The trailing twelve months (TTM) net income per share growth rate visualizes this margin of safety, where this metric equals -141.70. Brand stability in molecular testing and the implementation of ESG standards for biohazardous waste disposal support the market positions of ProPhase Labs, Inc. (PRPH).

This indicator measures the dynamics of net earnings per share over the last twelve months relative to the same period last year, allowing for the filtering of short-term fluctuations to assess real profitability. By analyzing the current EPS YoY TTM growth rate, a conservative investor can determine the effectiveness of ProPhase Labs, Inc. (PRPH) and its strategic transition toward scaling genetic testing and commercializing therapeutic products in the post-pandemic era.